Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats.
Aline de SouzaCauê Benito ScarimPaulo Cesar CotrimFernando Barbosa JuniorBruno Alves RochaLeandro Augusto CalixtoCristiano de Jesus CorreiaGabriel Lima Barros de AraujoRaimar LöbenbergNádia Araci Bou-ChacraAna Cristina Breithaupt-FaloppaPublished in: Nanomedicine (London, England) (2024)
Background: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 μg/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration.